<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00463008</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000346432</org_study_id>
    <secondary_id>NABTT-0302</secondary_id>
    <secondary_id>JHOC-NABTT-0302</secondary_id>
    <nct_id>NCT00463008</nct_id>
  </id_info>
  <brief_title>Pharmacologic Study of Methotrexate in Patients Undergoing Stereotactic Biopsy for Recurrent High-Grade Glioma</brief_title>
  <official_title>A Pharmacokinetic Study of Methotrexate Using an Intratumoral Microdialysis Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Brain Tumor Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting fluid from a brain tumor using a small catheter may help doctors learn&#xD;
      how much methotrexate gets into the tumor to kill the tumor cells. It may also help doctors&#xD;
      learn how methotrexate works in the brain and in the rest of the body.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how much methotrexate gets into the brain tumor by&#xD;
      collecting fluid directly from the tumor through a small catheter in patients undergoing&#xD;
      stereotactic biopsy for recurrent high-grade glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of using microdialysis to study distribution of systemically&#xD;
           administered methotrexate in the interstitial fluid within a tumor in patients&#xD;
           undergoing stereotactic biopsy for recurrent high-grade gliomas.&#xD;
&#xD;
        -  Determine the systemic and intratumoral pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients have an intratumoral microdialysis catheter placed while undergoing stereotactic&#xD;
      biopsy. Between 18-32 hours after placement of catheter, patients receive methotrexate IV&#xD;
      over 4 hours. Microdialysis perfusate and blood specimens are collected before, during, and&#xD;
      for 24 hours after methotrexate administration.&#xD;
&#xD;
      Patients are followed at 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of methotrexate levels in the brain extracelluar fluid vs in the serum</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and efficacy of the microdialysis catheter</measure>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed supratentorial grade III or IV astrocytoma of 1 of the&#xD;
             following subtypes:&#xD;
&#xD;
               -  Anaplastic astrocytoma&#xD;
&#xD;
               -  Anaplastic oligodendroglioma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
          -  Measurable, contrast-enhancing, residual disease by MRI or CT scan&#xD;
&#xD;
          -  Undergoing stereotactic biopsy for confirmation of tumor progression or&#xD;
             differentiation of tumor progression from treatment-induced effects&#xD;
&#xD;
               -  Patients with prior low-grade glioma that progressed after prior radiotherapy&#xD;
                  with or without chemotherapy and in need of stereotactic biopsy to confirm&#xD;
                  high-grade glioma are eligible&#xD;
&#xD;
          -  Must have received prior radiotherapy with or without chemotherapy&#xD;
&#xD;
          -  Planning to continue methotrexate therapy after participation on this study&#xD;
&#xD;
          -  No ascites or pleural effusions&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  SGOT ≤ 4 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except curatively treated basal cell or&#xD;
             squamous cell skin cancer or carcinoma in situ&#xD;
&#xD;
          -  Able to achieve hydration necessary for the use of methotrexate&#xD;
&#xD;
          -  Mini mental state exam score at least 15&#xD;
&#xD;
          -  No allergy to methotrexate&#xD;
&#xD;
          -  No other concurrent infection or medical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 3 months since prior radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  At least 1 week since prior salicylates, nonsteroidal anti-inflammatory drugs, or&#xD;
             sulfonamides&#xD;
&#xD;
          -  No concurrent prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  No concurrent chemotherapeutic agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey J. Olson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart A. Grossman, MD</last_name>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>June 21, 2013</last_update_submitted>
  <last_update_submitted_qc>June 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

